Galectin-3 Research

2020 Prospective Cohort Study: Gal-3 a Potential Biomarker of Vascular Calcification for Maintenance Hemodialysis (MHD) Patients

2020 Clinical Study: Galectin-3 a Biomarker for the Early Detection of Diabetic Kidney Disease (DKD)

2020 Review and Meta-analysis: Serum Galectin-3 is Associated with Increased Risk of Atrial Fibrillation Recurrence

2020 Preclinical Study: Gal-3 Signaling Pathway is Related to Pathogenesis of Atrial Fibrillation in Diabetes

2019 Preclinical Study: Galectin-3 Blocker Targets Galectin-3-Induced STAT3 Activation to Synergize with Chemotherapy Drug Paclitaxel Against Ovarian Cancer

2019 Preclinical Study: Galectin-3 Inhibition Improves Ischemic Heart Failure by Downregulating Galectin 3 and Reducing Myocardial Fibrosis

2019 Preclinical Study: Blockade of Galectin-3 Prevents Profibrotic and Proinflammatory Effects of Cardiotrophin-1 (CT-1) in Myocardial Fibrosis

2019 Preclinical Study: Blockade of Galectin-3 Prevents Cardiac Damage, Inflammation, and Fibrosis Following Kidney Injury

2019 Preclinical Study: Galectin-3 Inhibitor Reduces the Pro-Inflammatory, Pro-fibrotic, and Pro-osteogenic Response in Aortic valves in Patients Undergoing Aortic Valve Replacement

2019 Preclinical Study: Blockade of Galectin-3 Prevents Cardiac Fibrosis, Inflammation and Functional Alterations

2018 Preclinical Study: Modified Citrus Pectin Prevents Blood-Brain Barrier Disruption in Mouse Subarachnoid Hemorrhage by Inhibiting Galectin-3

2018 Preclinical Study: Blockade of Galectin-3 Protects Against Renal Injury and Fibrosis

2018 Preclinical Study: Inhibition of Galectin-3 Mitigates Diet-Induced Cardiac Lipotoxicity and Reduces Mitochondrial Damage

2018 Preclinical Study: Inhibition of Galectin-3 Reduces Inflammatory Mediators and Decreases Kidney Damage in Spontaneous Hypertension Model

2017 Preclinical Study: Galectin-3 Blockade Protects Vascular Tissue against Abdominal Aortic Aneurism

2017 Preclinical Study: Galectin-3 Blockade Prevents Cardiac Remodeling, Fibrosis and Inflammation Associated with Early Aortic Stenosis

2017 Preclinical Study: Galectin-3 Inhibition Reduces Size of Atherosclerotic Lesions

2017 Preclinical Study: Galectin-3 inhibition Blocks Inflammation, Fibrosis and Calcification in Aortic Valves

2016 Preclinical Study: Galectin-3 Blockade Reduces Renal Fibrosis, Inflammation and Damage

2016 Preclinical Study: Inhibition of Galectin-3 Prevents Adipose Tissue Remodeling in Obesity

2016 Preclinical Study: Galectin-3 Blockade Suppresses Neuropathic Pain and Decreases Proinflammatory Mediators Following Peripheral Nerve Injury

2015 Preclinical Study: Inhibition of Galectin-3 Prevents Obesity-Related Cardiovascular Remodeling

2013 Preclinical Study: Galectin-3 Blockade Reverses Vascular Hypertrophy and Fibrosis

2013 Preclinical Study: Modified Citrus Pectin Reverses Vascular Hypertrophy and Fibrosis, via Inhibition of Galectin-3

2012 American Heart Association Study: Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis

2012 Review: Circulating Galectin-3 in the Bloodstream: An Emerging Promoter of Cancer Metastasis

2011 Preclinical Study: Galectin 3 Aggravates Joint Inflammation and Destruction in Antigen-Induced Arthritis.

2011 Preclinical Study: Galectin-3 Blockade Reduces Kidney Disease Severity

Additional Galectin-3 Research Areas

Read More:  Galectin-3 in Arthritis & Inflammation

Read More: Galectin-3 in Bladder Cancer

Read More: Galectin-3 in Breast Cancer

Read More:  Galectin-3 in Prostate Cancer

Read More: Galectin-3 in Cancer Metastasis

Read More:  Cardiovascular/Circulatory System

Read More:  Galectin Structural/Binding/Function

Read More:  Galectin-3 and Gastrointestinal

Read More: Galectin-3 in Immunity & Autoimmunity

Read More:  Galectin-3 in Kidney

Read More:  Galectin-3 in Liver

Read More:  Galectin-3 in Lungs

Read More:  Galectin-3 Parasites

Read More: Galectin-3 in Diabetes

Read More:  Galectin-3 in Skin